Express Scripts-Medco Specialty Drug Market Share Would Exceed 52%
Executive Summary
The combination of Medco’s market-leading specialty drug pharmacy unit, Accredo, with Express Scripts’ specialty businesses would create a dominant player controlling more than 52% of the market, based on research by Pembroke Consulting.
You may also be interested in...
Deals Of The Week: AMAG/Allos, Pfizer/Icagen, Allergan/Vicept, BMS/Amira
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Express Scripts-Medco Deal Fits Post-Health Reform Realities, But Was Hastened By Contract Losses
Express Scripts’ merger agreement with Medco to form a mega-pharmacy benefits manager may fit into the new realities of the post-health care reform world, but it was also likely hastened by contract losses at Medco.
Deals Of The Week: AMAG/Allos, Pfizer/Icagen, Allergan/Vicept, BMS/Amira
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.